0001209191-23-056426.txt : 20231122 0001209191-23-056426.hdr.sgml : 20231122 20231122134857 ACCESSION NUMBER: 0001209191-23-056426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231120 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENSCHLER MARKUS MD CENTRAL INDEX KEY: 0001217598 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 231432561 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: BUILDING B, SUITE 450 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: BUILDING B, SUITE 450 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-20 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001217598 RENSCHLER MARKUS MD C/O CYTEIR THERAPEUTICS, INC. 99 HAYDEN AVE, BUILDING B, SUITE 450 LEXINGTON MA 02421 1 1 0 0 President and CEO 0 Common Stock 2023-11-20 4 M 0 56737 1.69 A 1045473 D Common Stock 2023-11-20 4 M 0 27900 1.20 A 1073373 D Stock Option (Right to Buy) 1.69 2023-11-20 4 M 0 56737 0.00 D 2033-02-03 Common Stock 56737 245863 D Stock Option (Right to Buy) 1.20 2023-11-20 4 M 0 27900 0.00 D 2030-02-24 Common Stock 27900 5073 D Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023. The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. /s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D. 2023-11-22